Opdivo is administered as an intravenous (IV) infusion, typically given every two to four weeks. The dosage and schedule may vary depending on the specific cancer being treated and the patient's response to the medication. Treatment with Opdivo can continue as long as the patient is benefiting from it and not experiencing unacceptable side effects.
